Skip to main content Help with accessibility Skip to main navigation

February 2020 updates to the website

The website has now been updated following February's LSCMMG

The following guidelines have been added/updated:

Lancashire and South Cumbria Self-Care and Access to OTC Medicines - Template Policy - New

Asthma Treatment Guideline for Children - New

Azathioprine and Mercaptopurine Shared Care Document - Update

Antipsychotic Shared Care Document - Update

Testosterone Shared care Document - Update

The following Items will be ratified and added to the website following March’s Joint Committee of CCGs (JCCCG) Meeting:

Octreotide - Secretory gastrointestinal disorders

Lanreotide - Secretory gastrointestinal disorders

Oscillating Positive Expiratory Pressure Devices - For Non – Cystic Fibrosis Bronchiectasis

Agomelatine - For the Treatment of Major Depressive Episodes in Adults

Nortriptyline - Chronic Neuropathic Pain

Lanreotide - Postural Tachycardia Syndrome (PoTS)

Octreotide - Postural Tachycardia Syndrome (PoTS)

Melatonin MR Tablets - Treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.

Melatonin liquid 1mg/ml - All indications including insomnia and Jet Lag

Melatonin 3mg tablets - All indications including insomnia and Jet Lag

Lusutrombopag (TA617) - Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure